Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/??l in 5 European Countries
- 1 December 1994
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 6 (6) , 553-562
- https://doi.org/10.2165/00019053-199406060-00008
Abstract
Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to...Keywords
This publication has 26 references indexed in Scilit:
- Medication costs associated with the care of HIV-infected patients.1993
- ZidovudinePharmacoEconomics, 1993
- Antimycobacterial Therapy for Disseminated Mycobacterium avium Complex Infection in Patients With Acquired Immunodeficiency SyndromeArchives of internal medicine (1960), 1992
- Progression and Clinical Outcome of Infection Due to Human Immunodeficiency VirusClinical Infectious Diseases, 1992
- AIDS surveillance in Europe: status at 31st March 1992. European centre for the epidemiological monitoring of AIDS.1992
- Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus InfectionAnnals of Internal Medicine, 1992
- Survival of Patients with Acquired Immune Deficiency Syndrome and DisseminatedMycobacterium aviumComplex Infection with and without Antimycobacterial ChemotherapyAmerican Review of Respiratory Disease, 1991
- Treatment of AIDS with combinations of antiretroviral agentsThe American Journal of Medicine, 1991
- Clinical economics. A guide to the economic analysis of clinical practicesJAMA, 1989
- Treating AIDS: the economic issuesHealth Policy, 1988